{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:25:06Z","timestamp":1787761506472,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nobilis Therapeutics","award":["001"],"award-info":[{"award-number":["001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Current treatments of panic disorder (PD) are limited by adverse effects, poor efficacy, and need for chronic administration. The established safety profile of subanesthetic concentrations of xenon gas, which is known to act as a glutamate subtype NMDA receptor antagonist, coupled with preclinical studies demonstrating its effects in other anxiety related conditions, prompted us to evaluate its feasibility and efficacy in treatment of patients with PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An open-label clinical trial of xenon\u2013oxygen mixture was conducted in 81 patients with PD; group 1 consisting of patients only with PD (N\u00a0=\u00a042); and group 2 patients with PD and other comorbidities (N\u00a0=\u00a039).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Based on the analysis of the results of a number of psychometric scales used in this study (SAS, HADS, CGI), several conclusions can be made: (1) xenon is a potentially effective modality in acute treatment of PD; (2) an anti-panic effect of xenon administration persists for at least 6\u00a0months after the completion of the active phase of treatment; (3) xenon inhalation is well tolerated, with the drop-out rates being much lower than that of conventional pharmacotherapy (5.8% vs. 15%); (4) the severity of depressive disorders that frequently accompany PD can be significantly reduced with the use of xenon; (5) xenon may be considered as an alternative to benzodiazepines in conjunction with cognitive-behavioral therapy as a safe modality in treatment of anxiety disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These data support the need for randomized double-blind clinical trials to further study xenon-based interventions.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>This clinical trial was retrospectively registered on April 14th, 2017 as ISRCTN15184285 in the ISRCTN database.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-017-1237-1","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T14:10:37Z","timestamp":1497363037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Xenon in the treatment of panic disorder: an open label study"],"prefix":"10.1186","volume":"15","clinical-trial-number":[{"clinical-trial-number":"isrctn15184285","registry":"10.18810\/isrctn"}],"author":[{"given":"Alexander","family":"Dobrovolsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Ichim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Bogin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,13]]},"reference":[{"issue":"6","key":"1237_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617\u201327.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"1237_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.euroneuro.2005.04.006","volume":"15","author":"RD Goodwin","year":"2005","unstructured":"Goodwin RD, et al. The epidemiology of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol. 2005;15(4):435\u201343.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1237_CR3","first-page":"900","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994. p. 900.","edition":"4"},{"issue":"22","key":"1237_CR4","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1056\/NEJMcp052466","volume":"354","author":"WJ Katon","year":"2006","unstructured":"Katon WJ. Clinical practice panic disorder. N Engl J Med. 2006;354(22):2360\u20137.","journal-title":"N Engl J Med"},{"issue":"6","key":"1237_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/0010-440X(91)90026-9","volume":"32","author":"JH Krystal","year":"1991","unstructured":"Krystal JH, et al. Characteristics of panic attack subtypes: assessment of spontaneous panic, situational panic, sleep panic, and limited symptom attacks. Compr Psychiatry. 1991;32(6):474\u201380.","journal-title":"Compr Psychiatry"},{"issue":"3","key":"1237_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4088\/JCP.v67n0305","volume":"67","author":"BF Grant","year":"2006","unstructured":"Grant BF, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(3):363\u201374.","journal-title":"J Clin Psychiatry"},{"key":"1237_CR7","unstructured":"Nutt D, Ballenger J, editors. Anxiety disorders: panic disorder and social anxiety disorder. Oxford: Blackwell Publishing; 2005. p. 280."},{"issue":"Suppl 8","key":"1237_CR8","first-page":"11","volume":"59","author":"Y Lecrubier","year":"1998","unstructured":"Lecrubier Y. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry. 1998;59(Suppl 8):11\u20134 (discussion 15\u20136).","journal-title":"J Clin Psychiatry."},{"issue":"4","key":"1237_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"B Bandelow","year":"2008","unstructured":"Bandelow B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders\u2014first revision. World J Biol Psychiatry. 2008;9(4):248\u2013312.","journal-title":"World J Biol Psychiatry"},{"issue":"11","key":"1237_CR10","first-page":"435","volume":"54","author":"AK Louie","year":"1993","unstructured":"Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry. 1993;54(11):435\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1237_CR11","first-page":"39","volume":"3","author":"DJ Katzelnick","year":"2006","unstructured":"Katzelnick DJ, et al. Time to response in panic disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone. Psychiatry (Edgmont). 2006;3(12):39\u201349.","journal-title":"Psychiatry (Edgmont)"},{"issue":"2","key":"1237_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","volume":"77","author":"M Lader","year":"2014","unstructured":"Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77(2):295\u2013301.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1237_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","volume":"38","author":"J Brett","year":"2015","unstructured":"Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152\u20135.","journal-title":"Aust Prescr"},{"issue":"8","key":"1237_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.eurpsy.2015.09.003","volume":"30","author":"TA Kurko","year":"2015","unstructured":"Kurko TA, et al. Long-term use of benzodiazepines: definitions, prevalence and usage patterns\u2014a systematic review of register-based studies. Eur Psychiatry. 2015;30(8):1037\u201347.","journal-title":"Eur Psychiatry"},{"key":"1237_CR15","first-page":"CD002024","volume":"5","author":"L Gowing","year":"2016","unstructured":"Gowing L, et al. Alpha(2)-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;5:CD002024.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6709","key":"1237_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/24525","volume":"396","author":"NP Franks","year":"1998","unstructured":"Franks NP, et al. How does xenon produce anaesthesia? Nature. 1998;396(6709):324.","journal-title":"Nature"},{"issue":"3","key":"1237_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/00000542-200203000-00028","volume":"96","author":"T Suzuki","year":"2002","unstructured":"Suzuki T, et al. The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3 receptors expressed in Xenopus oocytes. Anesthesiology. 2002;96(3):699\u2013704.","journal-title":"Anesthesiology"},{"issue":"4","key":"1237_CR18","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00000542-200010000-00034","volume":"93","author":"T Yamakura","year":"2000","unstructured":"Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology. 2000;93(4):1095\u2013101.","journal-title":"Anesthesiology"},{"issue":"3","key":"1237_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/ALN.0b013e3181cf894a","volume":"112","author":"C Bantel","year":"2010","unstructured":"Bantel C, Maze M, Trapp S. Noble gas xenon is a novel adenosine triphosphate-sensitive potassium channel opener. Anesthesiology. 2010;112(3):623\u201330.","journal-title":"Anesthesiology"},{"issue":"5","key":"1237_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/ALN.0000000000000635","volume":"122","author":"C Mattusch","year":"2015","unstructured":"Mattusch C, et al. Impact of hyperpolarization-activated, cyclic nucleotide-gated cation channel type 2 for the xenon-mediated anesthetic effect: evidence from in vitro and in vivo experiments. Anesthesiology. 2015;122(5):1047\u201359.","journal-title":"Anesthesiology"},{"issue":"4","key":"1237_CR21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.55782\/ane-2009-1754","volume":"69","author":"HU Weigt","year":"2009","unstructured":"Weigt HU, et al. Xenon blocks AMPA and NMDA receptor channels by different mechanisms. Acta Neurobiol Exp (Wars). 2009;69(4):429\u201340.","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"1237_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1124\/mol.65.2.443","volume":"65","author":"M Gruss","year":"2004","unstructured":"Gruss M. Two-pore-domain K+\u00a0channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol. 2004;65:443.","journal-title":"Mol Pharmacol"},{"key":"1237_CR23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.neubiorev.2014.10.016","volume":"47","author":"C Furini","year":"2014","unstructured":"Furini C, Myskiw J, Izquierdo I. The learning of fear extinction. Neurosci Biobehav Rev. 2014;47:670\u201383.","journal-title":"Neurosci Biobehav Rev"},{"issue":"8","key":"1237_CR24","doi-asserted-by":"publisher","first-page":"e106189","DOI":"10.1371\/journal.pone.0106189","volume":"9","author":"EG Meloni","year":"2014","unstructured":"Meloni EG, et al. Xenon impairs reconsolidation of fear memories in a rat model of post-traumatic stress disorder (PTSD). PLoS ONE. 2014;9(8):e106189.","journal-title":"PLoS ONE"},{"key":"1237_CR25","doi-asserted-by":"crossref","unstructured":"Stein DL, Stahl S, editors. Essential evidence-based psychopharmacology. 2nd edn. London: Cambridge University Press; 2012. p. 325.","DOI":"10.1017\/CBO9780511910395"},{"key":"1237_CR26","unstructured":"Naumov AV, Naumov SA, Lukin AV. Role of xenon in the treatment opium addiction. Voprosy narkologii. 2002;6:46\u201349."},{"key":"1237_CR27","unstructured":"Dobrovolsky B. Tsygankov\\using of subnarcotic doses of xenon in the treatment of panic disorder\\ABSTRACT BOOK \u201cmental health, direction and challenges\u201d p.55. WPA regional conference. Tbilisi, Georgia, 27-30 April, 2016."},{"key":"1237_CR28","unstructured":"Kuznetsov AV, Shamov SA. Xenon in the treatment of alcohol dependence during abstinence syndrome\/\/Proceedings of the scientific conference \u201c Xenon and xenon-saving technologies in medicine, 2005\u2033 Moscow, April 1\u20133, 2006, pp.129\u2013138 \u201cXenon and ksenonosberegayuschie technologies in medicine, 2005\u2033. The collection of reports. Ilina LA, editors. Atom Medical Center M.;2006. p.224."},{"key":"1237_CR29","unstructured":"Hritinin DF, Tsygankov BD. Ksenonoterapiya opium and alcohol addiction.\/\/Moscow, 2008. p.190."},{"key":"1237_CR30","first-page":"S25","volume":"2","author":"N Franks","year":"2002","unstructured":"Franks N, et al. Effects of xenon. Anesthesiology. 2002;2:S25\u201330.","journal-title":"Anesthesiology."},{"issue":"3","key":"1237_CR31","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/00000542-199909000-00011","volume":"91","author":"T Goto","year":"1999","unstructured":"Goto T, et al. Thermoregulatory thresholds for vasoconstriction in patients anesthetized with various 1-minimum alveolar concentration combinations of xenon, nitrous oxide, and isoflurane. Anesthesiology. 1999;91(3):626\u201332.","journal-title":"Anesthesiology"},{"issue":"3","key":"1237_CR32","first-page":"259","volume":"68","author":"JA Joyce","year":"2000","unstructured":"Joyce JA. Xenon: anesthesia for the 21st century. AANA J. 2000;68(3):259\u201364.","journal-title":"AANA J"},{"issue":"3","key":"1237_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/bja\/78.3.326","volume":"78","author":"T Marx","year":"1997","unstructured":"Marx T, et al. Effects on haemodynamics and catecholamine release of xenon anaesthesia compared with total i.v. anaesthesia in the pig. Br J Anaesth. 1997;78(3):326\u20137.","journal-title":"Br J Anaesth"},{"key":"1237_CR34","first-page":"132","volume":"9","author":"NE Burov","year":"2000","unstructured":"Burov NE, Makeev GN, Potapov VN. Applying xenon technologies in Russia. Appl Cardiopulm Pathophysiol. 2000;9:132\u20133.","journal-title":"Appl Cardiopulm Pathophysiol."},{"key":"1237_CR35","first-page":"87","volume":"9","author":"M Schmidt","year":"2000","unstructured":"Schmidt M, Papp-Jambor C, Schirmer U, Steinbach G, Marx T, Reinelt H. Is xenon anaesthesia cerebrotoxic? A Comparative study with halotane using protein S-100 determination. Appl Cardiopulm Pathophysiol. 2000;9:87\u201390.","journal-title":"Appl Cardiopulm Pathophysiol."},{"issue":"1","key":"1237_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00213-001-0941-x","volume":"160","author":"ML Molchanov","year":"2002","unstructured":"Molchanov ML, Guimaraes FS. Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats. Psychopharmacology. 2002;160(1):30\u20138.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1237_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s002130050499","volume":"135","author":"J Kotlinska","year":"1998","unstructured":"Kotlinska J, Liljequist S. A characterization of anxiolytic-like actions induced by the novel NMDA\/glycine site antagonist, L-701,324. Psychopharmacology. 1998;135(2):175\u201381.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1237_CR38","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1124\/jpet.110.172171","volume":"336","author":"MN Di Guilmi","year":"2011","unstructured":"Di Guilmi MN, et al. Pregabalin modulation of neurotransmitter release is mediated by change in intrinsic activation\/inactivation properties of ca(v)2.1 calcium channels. J Pharmacol Exp Ther. 2011;336(3):973\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1237_CR39","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/bja\/aet072","volume":"111","author":"C Stoppe","year":"2013","unstructured":"Stoppe C, et al. Feasibility and safety of xenon compared with sevoflurane anaesthesia in coronary surgical patients: a randomized controlled pilot study. Br J Anaesth. 2013;111(3):406\u201316.","journal-title":"Br J Anaesth"},{"issue":"7","key":"1237_CR40","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3174\/ajnr.A2522","volume":"32","author":"AP Carlson","year":"2011","unstructured":"Carlson AP, et al. Xenon-enhanced cerebral blood flow at 28% xenon provides uniquely safe access to quantitative, clinically useful cerebral blood flow information: a multicenter study. AJNR Am J Neuroradiol. 2011;32(7):1315\u201320.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"1237_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1148\/radiology.163.1.3823444","volume":"163","author":"RE Latchaw","year":"1987","unstructured":"Latchaw RE, et al. Adverse reactions to xenon-enhanced CT cerebral blood flow determination. Radiology. 1987;163(1):251\u20134.","journal-title":"Radiology"},{"issue":"2942","key":"1237_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1126\/science.113.2942.580","volume":"113","author":"SC Cullen","year":"1951","unstructured":"Cullen SC, Gross EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science. 1951;113(2942):580\u20132.","journal-title":"Science"},{"issue":"4","key":"1237_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/cc9051","volume":"14","author":"R Dickinson","year":"1951","unstructured":"Dickinson R, Franks NP. Bench-to-bedside review: molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection. Crit Care. 1951;14(4):229.","journal-title":"Crit Care"},{"issue":"5","key":"1237_CR44","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/01.anes.0000287061.77674.71","volume":"107","author":"R Dickinson","year":"2007","unstructured":"Dickinson R, et al. Competitive inhibition at the glycine site of the N-methyl-d-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. Anesthesiology. 2007;107(5):756\u201367.","journal-title":"Anesthesiology"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1237-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-017-1237-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1237-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T19:09:36Z","timestamp":1719256176000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-017-1237-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,13]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1186\/s12967-017-1237-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,13]]},"assertion":[{"value":"22 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"137"}}